MedPath

Corbus Pharmaceuticals, Inc.

Corbus Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Employees
1
Market Cap
$689.3M
Website
http://www.corbuspharma.com

Clinical Trials

53

Active:41
Completed:6

Trial Phases

3 Phases

Phase 1:45
Phase 2:5
Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials

Phase 1
45 (84.9%)
Phase 2
5 (9.4%)
Phase 3
3 (5.7%)

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Phase 1
Recruiting
Conditions
Solid Tumor
Interventions
Drug: CRB-601 monoclonal antibody
Drug: Anti-PD-1 monoclonal antibody
First Posted Date
2024-09-19
Last Posted Date
2025-06-03
Lead Sponsor
Corbus Pharmaceuticals Inc.
Target Recruit Count
156
Registration Number
NCT06603844
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

SCRI - Arizona Oncology Associates, Tucson, Arizona, United States

🇺🇸

The University of Arizona Cancer Center, Tucson, Arizona, United States

and more 23 locations

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor, Adult
Interventions
First Posted Date
2024-02-20
Last Posted Date
2025-06-03
Lead Sponsor
Corbus Pharmaceuticals Inc.
Target Recruit Count
348
Registration Number
NCT06265727
Locations
🇺🇸

O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham, Birmingham, Alabama, United States

🇺🇸

City of Hope Cancer Center, Duarte, California, United States

🇺🇸

Moores Cancer Centre at UC San Diego Health, San Diego, California, United States

and more 41 locations

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Phase 3
Completed
Conditions
Dermatomyositis
Interventions
First Posted Date
2019-01-23
Last Posted Date
2022-08-16
Lead Sponsor
Corbus Pharmaceuticals Inc.
Target Recruit Count
176
Registration Number
NCT03813160
Locations
🇺🇸

HonorHealth Neurology, Phoenix, Arizona, United States

🇺🇸

Mayo Clinic, Jacksonville, Florida, United States

🇺🇸

Attune Health Center, Beverly Hills, California, United States

and more 49 locations

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Phase 2
Completed
Conditions
Cystic Fibrosis
Interventions
First Posted Date
2018-03-01
Last Posted Date
2023-01-18
Lead Sponsor
Corbus Pharmaceuticals Inc.
Target Recruit Count
447
Registration Number
NCT03451045
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

Miller Children's Hospital, Long Beach, California, United States

and more 102 locations

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

Phase 3
Terminated
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
First Posted Date
2018-01-16
Last Posted Date
2021-03-29
Lead Sponsor
Corbus Pharmaceuticals Inc.
Target Recruit Count
365
Registration Number
NCT03398837
Locations
🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

Pacific Arthritis Care Center, Los Angeles, California, United States

🇺🇸

UCLA, Los Angeles, California, United States

and more 71 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.